Why did Japanese guidance favour early H. pylori treatment for stomach cancer prevention?

The recommendation and why it centres on timing

Helicobacter pylori is a common stomach infection that can contribute to stomach cancer. The Japanese guideline strongly recommends treating it at an early age for stomach cancer prevention. The rationale is not that treatment cancels every possible future cancer, but that earlier treatment is expected to offer the greatest protection before the stomach has undergone more advanced changes. Comparisons of people treated at different ages point in the same direction: a Taiwanese analysis estimated a 3% lower stomach cancer risk for each one-year earlier treatment.

After treatment, the risk is reduced but still present

A large Hong Kong database study followed 73,237 people who received H. pylori treatment. Over a median follow-up of 7.6 years, 200 of them still developed stomach cancer, so treatment did not eliminate the risk. For people aged 60 or older, the treated group's stomach cancer rate was 18% lower than expected in a matched general population. The clearest long-term reductions appeared 10 or more years after treatment, including in older age groups, which suggests older people can also benefit.

The comparisons behind this guidance are observational, not randomized experiments. Researchers compared treated people with expected rates in an age- and sex-matched general population and looked across age groups, rather than randomly assigning some people to early treatment and others to delayed treatment. The guideline itself notes that randomized trials directly comparing early versus delayed eradication are lacking. This does not undermine the recommendation, but it means the exact size of the timing effect cannot be proven from these data.